GICS Sector : Healthcare
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology.The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect.
Xeris Biopharma reported a robust financial performance for 2025, with total revenue growing 44% to $292 million, driven by strong demand across its three products: Recorlev, Gvoke, and Keveyis. Recorlev, the primary growth engine, delivered revenue of $139.3 million, more than doubling its sales year-over-year. The company achieved $59.4 million in adjusted EBITDA and reported net income on a full-year basis for the first time. Earnings per share (EPS) came in at $0.06, beating analyst estimates of $0.03.
Publication Date: Mar -09
The revenue growth was primarily driven by Recorlev, which is expected to continue its upward trajectory. For 2026, the company expects total revenue between $375 million and $390 million, representing over 30% growth at the midpoint. Recorlev is anticipated to remain the key growth driver, with Keveyis expected to remain steady and Gvoke growing in the high single-digit to low double-digit range. Partnership revenue is expected to contribute 5-10% to the total revenue.
The company is increasing investments in R&D by approximately $25 million to advance XP-8121, a promising new product, and in SG&A by approximately $45 million to support Recorlev's growth. Xeris Biopharma remains focused on driving rapid revenue growth, advancing its pipeline, and maintaining a strong balance sheet. The company is confident in its ability to remain adjusted EBITDA positive and grow on an absolute dollars basis compared to 2025.
With a P/S Ratio of 3.3 and an expected revenue growth rate of 30% for 2026, the company's valuation appears reasonable. However, the high P/E ratio of 174.5 indicates that the market has high expectations for future growth. Analysts estimate next year's revenue growth at 23.0%, which may not be sufficient to justify the current valuation. The company's strong balance sheet, with a Net Debt / EBITDA ratio of -2.09, provides a solid foundation for future investments and growth.
Xeris Biopharma is making progress with XP-8121, having completed interactions with the FDA and preparing for Phase III trials with a commercial-scale device and formulation. The company has also filed a patent infringement lawsuit against ANDA filers to protect its intellectual property, defending four Orange Book patents until 2040. This demonstrates the company's commitment to protecting its IP and ensuring the long-term viability of its products.
Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Mar -11
Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript
Mar -02
Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say
Mar -02
Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates
Mar -02
Why Are Shares Of Xeris Biopharma Falling Friday?
Feb -27
Unlocking Q4 Potential of Xeris Biopharma (XERS): Exploring Wall Street Estimates for Key Metrics
Feb -26
Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity
Feb -03
Analyzing Soleno Therapeutics (NASDAQ:SLNO) & Xeris Biopharma (NASDAQ:XERS)
Jan -29
Growing demand for convenient and effective treatments for severe hypoglycemia, periodic paralysis, and Cushing's syndrome, driven by increasing prevalence of these conditions, advancements in biotechnology, and Xeris Biopharma's innovative products, including Gvoke, Keveyis, and Recorlev, which offer improved patient outcomes and convenience.
Xeris Biopharma's royalty fees from licensed products, contract revenue from collaborations, and other income from miscellaneous sources are expected to drive growth. Increasing demand for innovative biopharmaceuticals, strategic partnerships, and expanding product portfolios are key growth drivers.
Gvoke is a ready-to-use, room-temperature stable glucagon injection for the treatment of severe hypoglycemia in people with diabetes.
Ogluo is a ready-to-use, room-temperature stable glucagon injection for the treatment of severe hypoglycemia in people with diabetes.
Gvoke HypoPen is a ready-to-use, room-temperature stable glucagon injection for the treatment of severe hypoglycemia in people with diabetes.
XeriSol is a ready-to-use, room-temperature stable glucagon injection for the treatment of severe hypoglycemia in people with diabetes.
Xeris Biopharma Holdings, Inc. operates in a highly competitive industry, but the threat of substitutes is mitigated by the company's focus on developing innovative and differentiated products.
Xeris Biopharma Holdings, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are often critical to customers' operations, making it difficult for them to negotiate prices.
Xeris Biopharma Holdings, Inc. relies on a few key suppliers for raw materials and services. While the company has some bargaining power due to its size, suppliers may still have some leverage in negotiations.
The biopharmaceutical industry is highly competitive, and new entrants can easily disrupt the market. Xeris Biopharma Holdings, Inc. must continually innovate and differentiate its products to stay ahead of new competitors.
The biopharmaceutical industry is highly competitive, with many established players and new entrants vying for market share. Xeris Biopharma Holdings, Inc. must be highly competitive in terms of pricing, product offerings, and innovation to maintain its market position.
| Value | |
|---|---|
| Debt Weight | 103.61% |
| Debt Cost | 9.93% |
| Equity Weight | -3.61% |
| Equity Cost | 9.93% |
| WACC | 9.93% |
| Leverage | -2866.81% |
Value: 6.4
Growth: 7.1
Quality: 5.4
Yield: 0.0
Momentum: 10.0
Volatility: 2.3
1-Year Total Return ->
Value: 6.2
Growth: 3.1
Quality: 5.1
Yield: 0.0
Momentum: 8.5
Volatility: 1.7
1-Year Total Return ->
Value: 6.4
Growth: 5.9
Quality: 3.1
Yield: 0.0
Momentum: 7.0
Volatility: 2.0
1-Year Total Return ->
Value: 2.5
Growth: 8.7
Quality: 7.1
Yield: 0.0
Momentum: 2.5
Volatility: 3.3
1-Year Total Return ->
Value: 8.0
Growth: 5.4
Quality: 5.6
Yield: 0.0
Momentum: 0.0
Volatility: 0.0
1-Year Total Return ->
Value: 7.5
Growth: 1.6
Quality: 4.6
Yield: 0.0
Momentum: 0.0
Volatility: 2.7
1-Year Total Return ->